MariaFleseriuMDFACE
Endocrinology • Portland, ORAdrenal Disease, Pituitary Disorders & Neuroendocrinology
Professor, Medicine (Endocrinology) and Neurological Surgery, Director Pituitary Center, Oregon Health and Science University
Dr. Fleseriu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3303 SW Bond Ave CH8N
Portland, OR 97239Phone+1 503-494-4314Fax+1 503-346-6810- Is this information wrong?
Summary
- Maria Fleseriu, M.D., F.A.C.E., is an endocrinologist and the director of the OHSU Pituitary Center.
Education & Training
Cleveland Clinic FoundationFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2002 - 2004
University of Medicine and Pharmacy TimisoaraClass of 1993
Certifications & Licensure
OR State Medical License 2006 - 2025
WA State Medical License 2022 - 2025
OH State Medical License 2002 - 2006- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Start of enrollment: 2011 Nov 04
- An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Start of enrollment: 2011 Aug 16
- Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Start of enrollment: 2014 Mar 06
- Join now to see all
Publications & Presentations
PubMed
- Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'.Stephan Petersenn, Maria Fleseriu, Shlomo Melmed> ;Nature Reviews. Endocrinology. 2024 Mar 20
- A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis.Ho, K., Wass, J., Raverot, G., Little, A., Castaño, J., Reincke, M., Lopes, M., Kaiser, U., Chanson, P., Gadelha, M., Fleseriu, M., Katznelson, L., Melmed, S.> ;The Lancet. Diabetes & Endocrinology. 2024 Mar 1
- Reply to 'The shift of therapeutic strategy for prolactinomas: surgery as the first-line option'.Petersenn, S., Fleseriu, M., Melmed, S.> ;Nature Reviews. Endocrinology. 2024 Jan 22
- Join now to see all
Journal Articles
- Graves Disease Exacerbation After Pituitary Adenomectomy for Cushing Disease Resulting in an Adrenal CrisisK. Aktas, Mehmet and Fleseriu, Maria and J. Weil, Robert and Faiman, Charles and T. Sergev, Orlin and Reddy, Sethu and Hamrahian, Amir, The Endocrinologist
- Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mif...Maria Fleseriu,corresponding author James W. Findling, Christian A. Koch, Sven-Martin Schlaffer, Michael Buchfelder, and Coleman Gross, J Clin Endocrinol Metab
- Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An UpdateMaria Fleseriu, MD, Endocrine Reviews
- Join now to see all
Lectures
- Guided Posters: Neuroendocrinology and PituitaryENDO 2019 - New Orleans, LA - 3/23/2019
- Management of Pregnancy Complicated by Pituitary and Adrenal DiseasesENDO 2019 - New Orleans, LA - 3/24/2019
- Neuroendocrinology and PituitaryENDO 2019 - New Orleans, LA - 3/23/2019
- Join now to see all
Press Mentions
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (Oral Octreotide) at ENEA 2022September 7th, 2022- Recordati Rare Diseases Announce Publication of Long-Term Outcomes from the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients with Cushing’s Disease in the European Journal of EndocrinologyAugust 31st, 2022
- Oral Octreotide Efficacy Maintained in More Than 90% of Adults with Acromegaly at 3 YearsJune 20th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
